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iii 
Introduction 
 
The evidence to support the efficacy and safety of a drug derives from randomised 
controlled trials (RCTs) [1]. The ethical basis of a RCT is provided by the principle of 
equipoise, stating that the randomization is allowed when there is genuine uncertainty on 
the actual benefit of the intervention under study. 
An RCT ideally should permit an unbiased estimation of the treatment effect (e.g., overall 
survival (OS) or disease-free survival (DFS)), through the comparison between an 
experimental treatment and a comparator, administrated in two separate arms. However, 
sometimes patients may be offered the possibility to cross over from one arm of the trial to 
the other, a phenomenon usually called selective crossover (SCO), in order to distinguish it 
from the studies in which crossover is planned. Other terms to refer to this switch are drop-
in or cross-in [2]. It can occur as a consequence of the diffusion of (un)favourable results 
of one treatment that is being compared, e.g. from interim analysis or from concurrent 
studies. In both cases the equipoise principle is challenged. If so, the investigators may 
offer patients the opportunity to cross over to the arm where the more promising treatment 
is administered. 
This thesis considers treatment crossover as the switching of patients randomised to the 
control group of an RCT on to the experimental treatment, at a certain point after 
randomisation. 
The occurrence of SCO breaks the randomization process and may give rise to problems in 
the data analysis and interpretation of results. In fact, in presence of SCO, the Intention to 
Treat (ITT) analysis, that is the analysis considering groups as randomised, will give an 
unbiased estimate of the experimental treatment assignment effect, but that effect will also 
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include the one of the experimental treatment administered to patients in the control group 
who switched. So the results of this type of analysis may not reflect the actual efficacy of 
the experimental intervention, and adjustments to allow for crossover are needed. 
 
My personal interest in this topic derives from the work that I conducted for my master 
degree thesis, when I presented the results of a systematic review on the efficacy and safety 
of a drug, i.e. trastuzumab, for the treatment of early and metastatic breast cancer. The 
work of my colleagues and me has been published in two articles [3,4]. In both 
adjuvant/neoadjuvant and metastatic settings, we observed that more than half of the 
included studies let patients in the control arm cross over to the trastuzumab arm at a 
certain point after randomisation. While in the metastatic setting crossover was permitted 
generally after progression, making it difficult to estimate the actual benefit of trastuzumab 
on OS, in the adjuvant/neoadjuvant setting it was permitted before disease progression, 
making it difficult to analyse and interpret both OS and DFS results. 
 
The present work aims to: 
(i) assess the prevalence of SCO in RCTs assessing the efficacy and safety of 
biological and hormonal therapies for breast cancer and published in the 
scientific literature; 
(ii) identify the reported statistical methods used to handle crossover, in particular 
when the effect of the experimental treatment is a time-to-event outcome; 
(iii) assess whether different statistical methods provide different results and 
interpretations. 
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Overview of the thesis 
 
Chapter 1 presents the review of the medical scientific literature carried out in order to 
assess the prevalence of the SCO in the field of breast cancer, and the approaches adopted 
to handle it. Details on the methods adopted to conduct the review are given, along with 
the presentation of the results, distinguished for adjuvant/neoadjuvant and metastatic 
setting. The Chapter closes with a discussion regarding the findings of the review and the 
needs for further research. 
Chapter 2 attempts to collect the more relevant approaches that have been considered in 
literature to address treatment crossover. 
Along with ITT analysis, other naïve methods include censoring patients at the time they 
cross over, or excluding them from the analysis. These methods will lead to biased results 
if the switching process is not random, because of selection bias. If patients who switch are 
picked completely at random, their exclusion from the analysis would not result in bias, but 
in the loss of power and increase of the uncertainty in the results. Instead, a switching 
process depending on patients’ characteristics implies informative censoring, and 
censoring or excluding from the analysis patients who cross over will lead to biased 
results. 
Another method described in literature is to consider the treatment as a time-varying 
covariate. This approach may be subject to selection bias, as groups may no longer be 
balanced after a patient is censored or excluded, and bias is likely if a patient’s probability 
of switching treatment is related to their underlying prognosis. 
Morden et al. [5] studied some statistical approaches for dealing with SCO. They 
considered naïve methods, as well as more complex ones, such as Robins and Tsiatis’s 
Rank Preserving Structural Failure Time Model (RPSFTM) [6]. The key assumption, 
though not always reasonable, of the RPSFTM method is the so-called “common treatment 
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effect” assumption: it is assumed that switching patients experience the same treatment 
effect, from the time they start taking the experimental treatment, as patients randomised to 
the experimental group from the beginning. 
Another approach considered in the paper by Morden et al., and evaluated in this thesis, is 
the one described in Loeys and Goetghebeur [8], who present a method for calculating the 
actual treatment effect in situations where all patients take their allocated treatment in one 
group, and compliance is assumed as “all-or-nothing” in the other. So, if a patient in this 
arm cross over, the switch is assumed to have happened right after the randomisation, and 
the patient is assumed to have only received the treatment he/she switched onto and not the 
treatment he/she was randomised to. 
The inverse probability of censoring weights (IPCW) method, introduced by Robins and 
Finkelstein [9], not evaluated in the paper by Morden et al., is also considered in the 
present work. The IPCW method do not assume the “common treatment effect”, but its 
fundamental assumption is the “no unmeasured confounders”, that is the requirement of 
data on all covariates that might influence the crossover. 
All these methods are presented in Chapter 2 of this thesis. 
In order to assess the potential bias associated with the methods described in Chapter 2, the 
actual effect of an intervention under study needs to be known, so a simulation study was 
performed. The idea was to reproduce a two-arm RCT, similar to one of the trials emerged 
from the review of the literature of Chapter 1: this work focuses the attention on the 
adjuvant/neoadjuvant setting, where the crossover is usually permitted before disease 
recurrence. Chapter 3 details the simulation study design and Chapter 4 presents the 
results. 
The main issues raised from the present work are discussed in Chapter 5, along with 
potential future developments of the research in this field. 
1 
Chapter 1 
Review of the literature 
 
In this chapter it is presented the review of the scientific literature conducted in order to 
evaluate the prevalence of the SCO among trials evaluating the efficacy and safety of the 
biological drugs and hormonal therapies for breast cancer, and the statistical methods used 
to handle it. 
 
1.1.Methods 
RCTs (phase III only) published between January 2000 and June 2015 in the Annals of 
Oncology (AoO), Journal of Clinical Oncology (JCO), Journal of the National Cancer 
Institute (JNCI), Lancet (L), Lancet Oncology (LO), New England Journal of Medicine 
(NEJM), assessing the efficacy and safety of biological drugs and hormonal therapy in 
breast cancer patients, were searched. We excluded chemotherapy agents because, in those 
years we selected as study time period, there were few new agents granting marketing 
authorisation: last innovative agents – doxorubicin pegylated and paclitaxel – were 
approved by the European Medicine Agency in 2000 [9]. 
The keywords used for the research were “random*”, “breast” and “cancer” – with the 
restriction that all words had to be present in the title or in the abstract. 
Trials were distinguished by the therapy setting they considered, i.e. adjuvant/neoadjuvant 
or metastatic. The prevalence was calculated as the percentage of trials in which crossover 
has occurred out of the total number of trials reflecting the inclusion criteria. 
For trials in which crossover has occurred, the following characteristics were recorded: 
primary end point, reason for crossover (i.e. interim analysis), number of patients totally 
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randomized, number and type of patients allowed to cross over, statistical methods used to 
analyse results after the crossover. When reported, characteristics of patients who crossed 
over in respect to patients who remained in the arm of original allocation was also 
recorded. 
If a trial reported the results for the same outcome (i.e. for overall survival (OS) or 
disease/progression-free survival (DFS/PFS)) in terms of hazard ratios (HR) from more 
than one type of analysis, the ratio of HRs (RHR), along with its 95% confidence interval 
(95%CI) was calculated in order to compare them. 
 
1.2. Results 
 
Figure 1. Flowchart of the bibliographic research 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
1706 references 
From 6 journals: NEJM, JNCI, Lancet, Lancet 
Oncology, JCO, Annals of Oncology 
Period limits: January 2000-June 2015 
351 references reporting the results of phase 
III or “uncertain phase” RCTs – full text 
retrieved 
128 references reporting the results of 85 
phase III RCTs: 
-  42 in a metastatic setting; 
-  43 in an adjuvant/neoadjuvant setting 
Crossover was present in 14 studies: 
-  10 out of 42 (24%) RCTs in a 
metastatic setting; 
-  10 out of 43 (23%) RCTs in an 
adjuvant/neoadjuvant setting 
1355 references excluded because they 
considered non-pertinent topics or because 
they considered phase II studies 
202 references excluded because the 
interventions were neither biological nor 
hormonal 
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The flowchart of the literature research is presented in Figure 1. Out of 1706 references 
totally retrieved (AoO 434; JCO 553; JNCI 192; L or LO 104; NEJM 423), 1355 were 
excluded because they did not consider treatments for breast cancer or because they 
considered phase II studies. The full text of the remaining 351 references was retrieved: 
202 were then excluded because the interventions were therapies neither biological nor 
hormonal and 21 because the study phase was unclear. The remaining 128 references 
reported the results of 85 RCTs, 43 of which enrolled women in early breast cancer and 42 
metastatic. 
 
Crossover was present in 20 RCTs (23.5%) equally distributed across settings: ten in 
adjuvant/neoadjuvant settings (23.3%) and ten in metastatic setting (23.8%). 
When SCO occurred, the methods used to analyse data were:  
1.  Intention To Treat (ITT) analysis; 
2.  Censored analysis; 
3.  Inverse Probability of Censoring Weighting (IPCW) analysis. 
In the ITT analysis, controls that crossed over are analysed as belonging to the control arm, 
despite the fact that they crossed over to the treatment intervention. 
In the censored analysis, follow-ups of controls that switched to the intervention arm are 
censored at the time when the crossover occurred.  
The IPCW analysis allows the estimation of the missing follow-ups of those controls who 
switched arm by using the information comprised in follow-ups of those controls who 
instead decided against crossing over and who were similar in terms of prognostic factors 
to their counterparts [8]. 
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1.2.1. Adjuvant/Neoadjuvant setting 
Characteristics of the ten RCTs (IMPACT, HERA, MA17, NSABP-B-33, BIG 1-98, 
NOAH, BCIRG-006, TEAM, B31, N9831) assessing efficacy and safety of treatments in 
the adjuvant/neoadjuvant setting in which SCO occurred are shown in Table 1.a. The 
studies B31 and N9831 were analysed and presented jointly, because they evaluate the 
same intervention, administered on a similar schedule. Five trials evaluated biological 
drugs and five hormonal therapies. Nine trials had DFS as primary outcome, one 
(IMPACT) had clinical tumour overall response. OS was always a secondary outcome. 
Two trials (IMPACT, NOAH) considered neoadjuvant strategies, and these are the trials 
with the lowest number of randomized patients (330 and 334 respectively). In five big 
trials (BIG 1-98, HERA, MA17, B31+N9831, with 8010, 3401, 5170, and 4390 
randomized patients respectively), crossover was allowed after positive results obtained at 
a pre-planned interim analyses. HERA and MA17 were the trials with the highest 
percentage of patients crossing over, 52% and 61% respectively. In three trials (IMPACT, 
NSABP-B-33, TEAM) patients were permitted to cross over after results from other 
similar studies were published leading to a protocol amendment. For two trials (BCIRG-
006, NOAH) the motivation for crossover was not reported. These trials had the lowest 
percentage of patients crossed over, 2.1% and 16% respectively. Other two trials 
(IMPACT, TEAM) did not clearly report the percentage of patients who crossed over. In 
two trials (BIG 1-98, HERA) the crossover was allowed only to patients who did not 
experience recurrence yet (HERA also required an adequate left ventricular ejection 
fraction); in the other studies, the crossover seemed to be offered to all patients in the 
control arm. 
All the studies presented ITT analyses; two studies (BIG 1-98, HERA) conducted censored 
analysis; two studies (BIG 1-98, MA17) conducted the IPCW analysis. The only study 
which conducted all three analyses is the BIG 1-98: in 2009 the results of the ITT and 
5 
censored analyses were published and in 2011 another paper reported an update of the ITT 
analysis and the IPCW analysis. 
Only two trials (HERA, MA17) reported the characteristics – in terms of age, previous 
therapy, menopausal status, hormone-receptor status, and lymph nodal status – of patients 
of the control arms who crossed over to the treatment arms, along with the characteristics 
of patients who did not. In both cases, patients in the SCO cohort compared with patients 
remaining in the control arm were more likely to be younger and have hormone-receptor-
positive disease. 
In table 2 are reported the results, expressed in HR (95%CI), for the three trials reporting 
censored or IPCW analysis, for DFS and OS respectively. The ITT analysis always seemed 
to be the more conservative one, although for the BIG 1-98 trial the RHRs both for OS and 
DFS were not statistically significant. OS results deriving from censored or IPCW analyses 
were more distant from the ones obtained with the ITT analysis in respect to DFS results. 
 
1.2.2. Metastatic setting 
Characteristics of the ten RCTs (Slamon 2001, Mouridsen 2003, TANDEM, AVADO, 
EGF104900, RIBBON-1, NCT00435409, NCT00938652, NCT00075764, CONFIRM) 
assessing efficacy and safety of treatments for metastatic breast cancer in which SCO 
occurred are shown in Table 1.b. All the trials but three (Mouridsen 2003, NCT00075764, 
CONFIRM) evaluated biological drugs. All the trials considered PFS as primary outcome 
and OS as secondary outcome. 
All the trials’ protocols permitted crossover to the experimental treatment arm for a patient 
in the control arm who experienced progression. RIBBON-1 was a four-arms trial, two 
controls and two experimental arms; after progression, patients in both the control arms 
were permitted to switch to the respective experimental arm. A particular case is 
represented by the Mouridsen 2003 trial, where two different hormonal therapies were 
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compared and in which patients at progression were permitted to switch to the other arm, 
irrespective of the arm in which they were initially allocated. 
The percentages of switched patients were over the 40% in all the studies but three 
(AVADO 36%, NCT00435409 36%, CONFIRM 2%). All the studies reported the ITT 
analysis and two (EGF104900, Mouridsen 2003) conducted censored analysis. 
Only one study (EGF104900) reported the main characteristics – age, performance status, 
prior therapies, hormone-receptor status – of the control arm by crossover status (crossover 
versus non-crossover), without statistically evaluating the differences between the two 
groups. 
In table 3 are reported the OS results, expressed in HR, for the two trials reporting 
censored analysis. Mouridsen 2003 calculated the median time to death in each group, 
from which it was possible to estimate the HR; too less information was provided to 
calculate the RHR. The HRs from the ITT and the censored analyses reported by the 
EGF104900 trial do not seem to differ significantly. 
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Table 1.a – Characteristics of the trials in which SCO occurred – Trials assessing efficacy of treatments in an adjuvant/neoadjuvant setting 
 Study 
BD/
HT 
Journal 
Year of 
publication* 
Year of 
reported 
SCO 
Primary End 
Point 
Motivation for 
SCO 
Pts totally 
randomized/ 
to be 
enrolled 
Pts crossed over ITT Cens IPCW 
1 IMPACT° HT JCO 2005 2005 
Clinical tumour 
OR 
After ATAC 
results 
330/330 Not reported √   
2 HERA BD NEJM,L,LO 2005-2011 2007 DFS Interim analysis 5102/4482 885/1698 (52%) √ √  
3 MA17 HT 
JCO,AoO,NEJ
M 
2003-2012 2008 DFS 
Interim analysis, 
unblinding 
5187/4800 1579/2587 (61%) √  √ 
4 NSABP-B-33 HT JCO 2008 2008 DFS 
After MA17 
(interim analysis) 
results 
1598/3000 344/779 (44%) √   
5 BIG 1-98 HT NEJM,JCO,LO 2005-2011 2009 DFS 
Planned interim 
analysis 
8010/8028 619/2459 (25%) √ √ √ 
6 NOAH° BD L 2010 2010 DFS (EFS) Not reported 235/232 19/118 (16%) √   
7 BCIRG-006 BD NEJM 2011 2011 DFS Not reported 3222/3150 23/1073 (2.1%) √   
8 TEAM HT L 2011 2011 DFS After IES results 9779/9300 Not reported √   
9+
10 
B31+N9831 BD NEJM,JCO 2005-2014 2014 DFS 
Planned interim 
analysis 
4390/4130 413/2018 (20%) √   
* If more than one publication refers to the same study, the year of first publication and the year of last publication are reported 
Pts=patients 
NEJM=New England Journal of Medicine; JNCI=Journal of the National Cancer Institute; L=Lancet; LO=Lancet Oncology; JCO=Journal of Clinical Oncology; AoO=Annals of Oncology 
DFS=Disease Free Survival; OR=Objective Response 
HT=Hormonal therapy; BD=Biological Drug 
° Neoadjuvant trials 
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Table 1.b – Characteristics of the trials in which SCO occurred – Trials assessing efficacy of treatments in a metastatic setting 
 Study 
BD/
HT 
Journal 
Year of 
publication* 
Year of 
reported 
SCO 
Primary End 
Point 
Motivation for 
SCO 
Pts totally 
randomized/ 
to be 
enrolled 
Pts crossed over ITT Cens IPCW 
1 Slamon 2001 BD NEJM 2001 2001 PFS After progression 469/450 154/234 (66%) √   
2 
Mouridsen 
2003 
HT JCO 2003 2003 PFS After progression 907/907 
233/458 (51%) + 
226/458 (49%) 
√ √  
3 TANDEM BD JCO 2009 2009 PFS After progression 208/208 73/104 (70%) √   
4 AVADO BD JCO 2010 2010 PFS After progression 736/705 83/231 (36%) √   
5 EGF104900 BD JCO 2010-2012 2010 PFS After progression 296/296 77/145 (53.1%) √ √  
6 RIBBON-1 BD JCO 2011 2011 PFS After progression 1237/1200 
112/206 (54.4%) + 
105/207 (50.7) 
√   
7 NCT00435409 BD JCO 2013 2013 PFS After progression 432/430 77/215 (36%) √   
8 NCT00938652 BD JCO 2014 2014 PFS After progression 519/420 161/258 (62%) √   
9 NCT00075764 HT NEJM 2012 2012 PFS After progression 695/690 143/345 (41%) √   
10 CONFIRM HT JNCI 2014 2014 PFS After progression 736/834 8/374 (2%) √   
* If more than one publication refers to the same study, the year of first publication and the year of last publication are reported 
Pts=patients 
NEJM=New England Journal of Medicine; JNCI=Journal of the National Cancer Institute; L=Lancet; LO=Lancet Oncology; JCO=Journal of Clinical Oncology; AoO=Annals of Oncology 
PFS=Progression Free Survival; EFS=Event Free Survival 
HT=Hormonal therapy; BD=Biological Drug 
° Neoadjuvant trials 
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Table 2 – DFS and OS results, expressed in HR (95%CI), for the three trials assessing efficacy 
and safety of treatments, in an adjuvant/neoadjuvant setting, reporting censored or IPCW 
analysis – results from the most recent publication for each trial are reported. RHRs (95%CI) 
were calculated in order to compare the results from different type of analyses (ITT as reference 
analysis). 
Study 
 Type of analysis   
 ITT Censored IPCW  RHR 
       DFS 
HERA (2011)  0.76 (0.66;0.87) 0.69 (0.59;0.79)   0.91 (0.66; 0.87) 
BIG 1-98 (2011)  0.86 (0.78;0.96)  0.82 (0.74;0.92)  0.95 (0.82; 1.11) 
MA17 (2012)  0.68 (0.56;0.83)  0.52 (0.45;0.61)  0.76 (0.60; 0.98) 
       OS   
HERA (2011)  0.85 (0.70;1.04) 0.53 (0.44;0.65)   0.62 (0.47; 0.82) 
BIG 1-98 (2011)  0.87 (0.77;0.99)  0.79 (0.69; 0.90)  0.91 (0.76; 1.09) 
MA17 (2012)  0.99 (0.79;1.24)  0.61 (0.52;0.71)  0.62 (0.47; 0.81) 
 
Table 3 – OS results, expressed in HR (95%CI), for the two trials assessing efficacy and safety of 
treatments, in a metastatic setting, reporting censored or IPCW analysis – results from the most 
recent publication for each trial are reported. RHRs (95%CI) were calculated in order to 
compare the results from different type of analyses (ITT as reference analysis). 
Study 
 Type of analysis  RHR 
 ITT Censored IPCW   
EGF104900 (2012)  0.74 (0.57;0.96) 0.80 (0.56;1.12)   1.08 (0.70; 1.67) 
Mouridsen 2003 (2003)  0.88 (p=0.53) 0.71 (nr)   - 
nr = not reported 
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1.3. Review findings 
 
Between January 2000 and June 2015, one out of five RCTs assessing efficacy of 
innovative biological drugs and hormonal therapy for breast cancer permitted patients to 
cross over at a certain point during the course of the study. From a clinical standpoint, 
early discontinuation of RCT due to unequivocal observed benefit, harm or futility are 
always justified by ethical issues. An early interruption for benefit leads to stopping further 
recruitment in a potential inferior arm, and patients randomized to the control arm can opt 
to cross over to receive the experimental treatment. However, from a methodological 
standpoint, this approach leads to uncertainties surrounding the true magnitude of the 
actual effect. 
The scenario might be different when considering the early or the advanced disease setting.  
Indeed, it is well accepted that patients with metastatic disease, at the time of disease 
progression, are given the opportunity to switch to the arm with the more promising 
therapy. This approach has no effect on the earlier measures of treatment effect such as 
PFS, which represents the primary outcome in all the found studies. On the other hand, the 
crossover can definitively preclude the possibility to demonstrate an OS benefit, which is 
often considered the ultimate test of efficacy.  
The situation is even more critical in the adjuvant setting, where SCO is generally offered 
to patients still free of disease recurrence, thus affecting the clear interpretation of both 
DFS and OS. The scientific community has to deal with the ethical imperative to offer the 
best treatment to those patients who decide to enter a clinical trial, and with the need of 
obtaining the most clean evidence to be applied in the whole population. Indeed, all the 
interventions which raise uncertainties in data interpretations can delay the full acceptance 
of a clinically relevant intervention.  
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All the studies included in the present analysis were always analyzed following the ITT 
approach, which is the traditional analysis. According to the ITT principle, patients are 
analysed in their assigned treatment arm regardless of the actual treatment received. 
Therefore, when a substantial fraction of the patients from the less active treatment cross to 
the more effective treatment, the net benefit of the latter tends to be reduced. Censored 
analysis can be used to account for disruptions in treatment allocation. This approach 
censures patients after crossover, and can be more informative on the real performance of 
the experimental arm. Only 2/10 adjuvant and 2/10 metastatic studies included in the 
present analysis reported the censored analysis. The censored analysis was associated with 
an increased benefit for the experimental arm as compared to the ITT analysis. However, 
censored analysis can introduce bias itself, in particular when censored patients are more 
likely or less likely to experience the event than uncensored patients (informative 
censoring). In both HERA and MA17 trials, patients in the SCO cohort were more likely to 
be younger and have hormone-receptor-positive disease, as compared to patients remaining 
in the control arm. 
One of the most recent type of analysis, IPCW [8], which accounts for prognostic factors, 
was rarely used (2/10 adjuvant trials). Similarly to the censored analysis, IPCW analysis 
led to results which favour the experimental arm in respect to the ITT analysis, which 
instead tends to dilute the treatment effect. By the way, the adjustment made by the IPCW 
analysis is valid only if the variables which determine crossover are known and 
measurable, as pointed out by Rimawi et al. [10]. This is not always possible, leaving the 
choice to imply this type of analysis doubtful. 
The main limitation of the research presented in this chapter is the fact that only articles 
that appeared within a 15-year period were searched in six selected medical journals, 
reasoning that these ones published most of the RCTs in breast cancer. It would be helpful 
to further investigate the phenomenon with a more comprehensive literature research. The 
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prevalence and impact of SCO in fields other than breast cancer should also be studied. 
The magnitude and direction of the potential bias introduced by the SCO needs to be 
clearly evaluated, as well as the impact on the results for different effect sizes when results 
concern safety and when the reason for switching depends on a combination of prognostic 
factors. 
However, the lack of an appropriate reporting is not a trivial concern. In 2005, Montori et 
al. published a systematic review of RCTs stopped early for benefit [11], which might lead 
to SCO, in which they highlighted the lack of adequately reported such an important 
information as the motivation to stop the trial. More attention should be paid by the authors 
also in the reporting of the characteristics of patients to whom the crossover is offered. 
Considering the increasing frequency of the phenomenon, the Consolidated Standards of 
Reporting Trials (CONSORT) statement [1] could be modified in order to recommend the 
specification of that information, fundamental for a better understanding and interpretation 
of the results of the trial. 
 
This chapter clearly points out that the treatment crossover phenomenon is quite common 
in breast cancer trials. Different methods may lead to different results and interpretations, 
but there is still no consensus on the appropriate approach to deal with SCO.  
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Chapter 2 
Methods for dealing with selective cross over 
 
Chapter 1 highlighted the need to find appropriate strategies to deal with treatment 
crossover. 
The present chapter describes the most relevant existing statistical approaches to handle 
SCO. These methods will be then assessed through simulation, as explained in Chapter 3, 
and the results of the simulations will be presented in Chapter 4. 
 
2.1.Naïve methods 
 
2.1.1. Intention-to-treat (ITT) analysis 
As emerged from the medical literature review presented in Chapter 1, all authors use an 
ITT analysis. According to this approach, patients are analysed depending on which 
treatment group they were initially allocated to, and data from all randomised patients is 
used.  
ITT analysis results should always be reported, as this method reflects the design of the 
study. By the way, if the experimental treatment is actually superior to the control, and a 
fraction of patients have crossed over from the control to the experimental arm, the ITT 
analysis will tend to dilute the magnitude of the experimental treatment effect estimate, 
making it appear more similar to the control effect. 
A Cox proportional hazard model is usually fitted in order to estimate the treatment effect. 
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2.1.2. Censored analysis 
A possible approach is to censor patients at the time of crossover; this method is used in 
two out of ten breast cancer trials where SCO has occurred, as seen in Chapter 1. 
Groups may actually no longer be balanced after patients are censored, so this type of 
analysis may be exposed to selection bias, and this is particularly true if patients’ 
probability of crossing over is related to their underlying prognosis. 
 
2.1.3. Treatment as a time-varying covariate 
Although no study from the review in Chapter 1 has reported it, an approach to deal with 
SCO is considering the treatment as a time-varying covariate. 
It is an extension of the Cox proportional hazards model: 
λi(t) = λ0(t) exp(βXi(t)) 
where λ0(t) is the baseline hazard function and Xi(t) takes a value of zero when a patient is 
on control and 1 when on experimental treatment. 
This approach also may be subject to selection bias if SCO is related to prognosis. 
 
2.2. More complex methods 
 
2.2.1. Inverse Probability of Censoring Weighting (IPCW) analysis 
This method is rarely used in RCTs assessing the efficacy of biological drugs and 
hormonal therapies for breast cancer, and in particular only in the adjuvant setting, as 
described in Chapter 1. 
Although in another clinical field, Robins and Finkelstein [8] firstly used the IPCW 
approach to try to overcome noncompliance issue. It can be thought as a method to 
improve the censoring strategy described in paragraph 2.2. Instead of simply censoring 
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patients, the covariates of censored patients are considered in order to try to remove 
selection bias. 
IPCW method creates a scenario of missing follow‐up data by censoring the follow‐up of 
each subject at the time of crossover. The weight in the analysis for time periods after 
crossover is then equal to 0. 
For subjects in the control with similar characteristics that do not cross over, IPCW method 
assigns bigger weights to “re‐create” the population that would have been observed 
without crossover. So, a patient in the control arm who remains in the control arm will be 
assigned a weight > 1 if other patients with similar characteristics crossed over. Weights 
are based on factors affecting a patient’s decision to cross over. 
 
The method relies on the assumption usually called “no unmeasured confounders” in the 
censoring process. Conditional on the treatment arm R and on the recorded history ?̅?(𝑡) of 
the time-dependent covariates 𝑉(𝑡), the cause-specific hazard of censoring C at time 𝑡 does 
not further depend on the possibly unobserved failure time 𝑇: 
𝜆𝐶  (𝑡 |?̅?(𝑡), 𝑅, 𝑇, 𝑡 < 𝑇)  = 𝜆𝐶  (𝑡 | ?̅?(𝑡), 𝑅, 𝑡 < 𝑇) 
where 
𝜆𝐶 = cause-specific hazard of censoring C 
 𝑅 = treatment arm 
 𝑇 = possibly unobserved failure time 
 ?̅?(𝑡) = { 𝑉 (𝑥);  0 ≤  𝑥 <  𝑡 } is the recorded history up to time 𝑡 
V(x) is a vector of all measured time-dependent factors for failure time 
recorded at time x. 
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This assumption specifies that, within a treatment arm, patients censored at time 𝑡 have the 
same distribution of failure time as those uncensored at time 𝑡 with the same recorded 
history. 
 
Given the “no unmeasured confounders” assumption, the IPCW estimators based on the 
time-dependent prognostic factors can be constructed as follow. 
Time-dependent Cox proportional hazards models are used to estimate the treatment-
specific hazards of censoring conditional on time-dependent prognostic factors (reason for 
censoring can differ between arms). 
𝜆𝐶(𝑡 | ?̅?(𝑡), 𝑅, 𝑡 < 𝑇) =  𝜆0𝑅(𝑡) exp (α𝑅
′ ?̅?(𝑡))  
 
IPCW Kaplan-Meier (KM) estimator for failure differs from the ordinary KM estimator for 
failure by weighting the contribution of a subject at risk at time 𝑡 by the inverse of an 
estimate of the conditional probability of having remained uncensored until time 𝑡, based 
on the fit of this model. 
 
By denoting 
    ?̂?𝑅    as Cox partial likelihood estimate of 𝛼𝑅 in treatment arm 𝑅 
𝑋 =  𝑚𝑖𝑛(𝑇, 𝐶) 
 𝑌(𝑢)  =  𝐼 (𝑥 ≥  𝑢)  as the “at risk” indicator  
 𝜏 =  𝐼 (𝑇 =  𝑥) as the failure indicator (1 = failure; 0 = censored) 
 
an estimate of the conditional probability of patient i having remained uncensored until 
time 𝑡 is provided by the time-dependent extension of KM product limit estimator of 
censoring 
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is the Cox estimator of the baseline hazard function for censoring λ0R in arm R. 
 
The subject-specific weight can be defined 
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Where )(ˆ 0 tK i is the usual treatment arm specific KM estimator of the probability of being 
uncensored by the time t in treatment Ri. 
So the IPCW KM estimator for failure in treatment arm r, r ∈ {0, l}, differs from the 
ordinary KM estimator for failure only in that the contribution of a subject at risk at any 
time 𝑋𝑖 is weighted by the subject-specific weight )(ˆ ii XW . 
The IPCW KM estimate of the treatment arm specific marginal probability of remaining 
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)()( rRIXW iiii   is the estimate of the number of subjects in arm r who would have been 
observed to fail at time Xi in the absence of any censoring and  
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)()()(  is the estimate of the number of subjects in arm z who would 
have been at risk at time Xi in the absence of any censoring. 
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)|(ˆ rtST  estimates the probability )|( rtST  of surviving without failure until time t in the 
absence of censoring. 
 
It is possible to compare the marginal survival in the two arms by using the Cox 
proportional hazards model 
𝜆𝑇 (𝑡 | 𝑅)  =  𝜆0 (𝑡)𝑒
𝛽𝑅 
 
The IPCW Cox partial likelihood score for β is 
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The estimating equation 0  )U(  gives a consistent and asymptotically normal estimator 
of parameter β. 
 
The major concerns on this method are the “no unmeasured confounders” assumption, 
which is untestable, and the fact that the IPCW approach cannot work if there are any 
covariates which ensure (that is, the probability equals 1) treatment crossover will or will 
not occur. 
 
2.2.2. Loeys and Goetghebeur estimator 
An approach to estimate the real treatment efficacy in situations where all patients take 
their allocated treatment in one arm of the trial and compliance is “all-or-nothing” in the 
other arm is reported by Loeys and Goetghebeur [7]. “All-or-nothing” means that, if a 
patient allocated to that arm crosses over to the other one, the crossover is assumed to have 
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happened at the very beginning, right after the randomisation, and the patient is assumed to 
have only received the treatment he/she switched onto. 
The authors present the method by considering that all patients in the control arm comply 
fully, and patients in the experimental arm may either comply fully (complier) or not at all 
(non-complier). Individuals in the control arm are also classified as compliers and 
noncompliers according to how they would have behaved if they had been randomized to 
the experimental arm. This thesis considers the opposite case in which all patients in the 
experimental arm comply fully, and patients in the control arm may either comply fully or 
not at all. 
The proportion of noncompliers, α, is assumed to be the same in both arms due to 
randomisation; this assumption is often called “exclusion restriction assumption”. 
The probability of survival to time t is denoted by Sn0(t) and Sc0(t) for noncompliers and 
compliers randomized to control, and Sn1(t) and Sc1(t) for noncompliers and compliers 
randomized to the experimental arm. For each arm j = 0, 1: 
Sj(t) = α*Snj(t)+(1 − α)*Scj(t) 
Let us assume that allocation to intervention has no effect on noncompliers and has hazard 
ratio 𝜓 for compliers: 
Sn0(t) = Sn1(t) 
Sc0(t) = 𝑆𝑐1(𝑡)
1/𝜓 ↔  𝑆𝑐0(𝑡)
𝜓  = Sc1(t) 
The compliance-adjusted intervention effect estimate, ?̂?, is obtained by using Kaplan–
Meier estimates of Sn0(t) and Sc0(t) to estimate the survivor function in the experimental 
arm: 
𝑆1
∗̂(t| 𝜓) = ?̂?*?̂?𝑛0(t)+(1 − ?̂?)* ?̂?𝑐0(𝑡)
1/𝜓 
 
A value of 𝜓 is found at which this quantity matches the observed survival in the 
experimental arm. 
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Defining 
𝛬1 
∗̂ (𝑡|𝜓) =  −𝑙𝑜𝑔𝑆1
∗̂(t| 𝜓), 
𝐺1
∗(𝜓) =  ∑ [𝛬1 
∗̂ (𝑇𝑗|𝜓) − 𝛿𝑗]
𝑗
 
where the sum is over all individuals in the experimental group, 𝑇𝑗 is the censoring/event 
time for the jth individual, and 𝛿𝑗 is the failure indicator for the jth individual. 
𝐺1
∗(𝜓) can be thought of as the difference between observed and expected events in the 
experimental arm, based on predictions from the control arm if the hypothesized 𝜓 is 
correct. 
The value of 𝜓 that represents the final estimate of the compliance-adjusted intervention 
effect is found by solving 𝐺1
∗(𝜓) = 0. 
The authors demonstrate that  
𝐺1
∗(𝜓)~𝑁{0, 𝑠(𝜓)2} 
where 𝑠(𝜓)2 =  2 ∑ 𝛬1 
∗̂ (𝑇𝑗|𝜓)𝑗 . 
 
Confidence limits for  𝜓 are found, as described in Kim and White [12], by solving 
𝐺1
∗(𝜓) = ±zcrit 𝑠(𝜓), 
where zcrit is the critical value for the appropriate significance level. 
The estimation of the point estimate and confidence limits can be obtained using a loop 
employing interval bisection. The target value is firstly set as either 0, − zcrit 𝑠 or + zcrit 𝑠, 
depending whether the point estimate, lower confidence limit, or upper confidence limit is 
being estimated. Then, minimum and maximum values of 𝜓 are initialized. 
At the start of each run of the loop, 𝜓 is defined as the midpoint of the current minimum 
and maximum values, and 𝐺1
∗(𝜓) is calculated. If 𝐺1
∗(𝜓) is greater than the target value, 
the minimum is reset to the value of 𝜓 used in this run, or if it is less than the target, the 
maximum is reset to 𝜓. The loop is then run again, applying these new minimum and 
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maximum values, unless the difference between them is less than a user-defined value (e.g. 
0.01). 
 
An important limitation of this method is clearly the all-or nothing compliance assumption, 
as this type of compliance is only likely to occur in very specific situations. By the way it 
remains interesting to evaluate the method in a simulation. The exclusion restriction 
assumption, though untestable, is likely to hold in the majority of the cases, due to 
randomisation.  
 
2.2.3. Rank Preserving Structural Failure Time Model (RPSFTM) 
Robins and Tsiatis [6] developed the RPSFTM in order to estimate causal effects in the 
presence of non-compliance in an RCT. This method identifies the treatment effect by 
using the randomisation of the trial, observed survival and observed treatment history. 
An assumption of this method is that, given two patients i and j, if i failed before j when on 
one treatment, then i would also fail before j if both patients took the same alternative 
treatment. That is way this approach is called “rank preserving”. 
Another important assumption is the so called “common treatment effect”: the treatment 
effect is assumed to be the same for patients crossing over to a treatment as for those 
initially allocated to receive it. 
 
The observed event time T is related to an underlying event time U that would have been 
observed in the absence of treatment, through an accelerated life model. The parameter 𝜓 
of the model represents the factor by which life is accelerated by treatment and is estimated 
as the value at which U is balanced between the treatment groups (on a user-specified test). 
The method splits the observed event time for each patient (Ti) into two: 
Ti = T0i + T1i 
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where T0i and T1i are the lengths of time that the patient spent on control and on 
experimental treatment before the event, respectively. 
For patients randomised to the experimental treatment, who do not cross over onto the 
control treatment, T0i is equal to 0. 
For patients randomised to the control group who do not switch onto the experimental 
treatment, T1i is equal to 0, while for patients who cross over both T0i and T1i will be 
greater than 0.  
The observed event time Ti is related to counterfactual treatment-free event time Ui by a 
causal model 
Ui = T0i + 𝑒𝜓0 T1i 
where 𝜓0 is the true causal parameter. 
Assuming that U ⫫ R, where Ri = 0/1 indicates the randomized treatment arm, for any 
given value of 𝜓, the hypothesis 𝜓 =  𝜓0is tested by computing  
Ui (𝜓)= T0i + 𝑒𝜓 T1i 
and calculating Z(𝜓) as the test statistic for the hypothesis U(𝜓) ⫫ R. 
Basically Ui is estimated using the causal model for each value of 𝜓, and the true value of 
𝜓 is that for which U(𝜓) is independent of randomised groups. 
A log-rank test can be used for testing the hypothesis that the baseline survival curves are 
identical in the two treatment groups. Z(𝜓) is a step function, and the point estimate is the 
value of 𝜓 for which Z(𝜓) crosses 0.  
 
The RPSFTM makes different important assumption: 
- if a patient fails before another individual on one treatment arm, he/she will also fail 
before that other individual on all other treatment regimens; 
- the time at which a patient would experience the outcome if never treated is not related to 
the allocation arm (randomisation assumption); 
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- the treatment effect does not change in relation to the time in which a patient starts 
receiving the treatment (common treatment effect assumption). 
The randomisation assumption should be reasonable in the context of an RCT. The 
common treatment effect, instead, could be a concern because it is assumed that there is 
not a difference in the treatment effect in patients initially randomised to the intervention 
compared to patients in the control group who cross over. 
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Chapter 3 
Simulation study design 
 
The effort to estimate the real effect of an intervention is of crucial importance, and SCO 
makes it undoubtedly more difficult. 
Chapter 1 has described SCO in the field of therapies for breast cancer, highlighting the 
non-negligible spread of this phenomenon. The most relevant methods for dealing with 
SCO were presented in Chapter 2. 
In order to assess the bias that the different methods may lead to, the real effect of an 
intervention under study needs to be known. This is possible through a simulation study. 
 
The attention is focused on the adjuvant/neoadjuvant setting, where the crossover is 
offered before disease recurrence. So a two-arm RCT similar to one emerged from the 
medical literature search was simulated. 
In the first paragraph of this chapter, the hypothesized scenarios are explained, while in the 
second one the description of the performance measures is given. 
 
3.1. Scenarios’ description 
A sample size of 3000 was chosen, with 1500 patients allocated each to receive the 
experimental treatment or the control. 
As mentioned in previous chapters, bias is likely to occur when patients with different 
underlying prognoses have different probabilities of crossing over between treatment arms. 
In order to explore this, patients were divided into two groups, those called “with a good 
prognosis”, or “at low risk”, and those “with a poor prognosis”, or “at high risk”. 
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The probability of being “at low risk” was set at either 30% or 70%. 
Survival times were generated from an exponential distribution. 
The rate chosen for patients “at low risk” was 0.05, while the one for patients “at high risk” 
was 0.25. Randomisation guarantees that the proportion of patients “at low risk” and “at 
high risk” is balanced between treatment arms. 
 
Three different scenarios for the actual treatment effect were hypothesized: the hazard ratio 
(HR) was chosen to be 0.55 (β = -0.598), to represent a highly effective treatment, or 0.80 
(β = -0.223), a less effective treatment, or 1 (β = 0) to represent a treatment with no effect. 
All patients were assumed to have entered the trial at the same time, and an administrative 
censoring at 3 years was considered, to represent the end of follow-up. 
 
The crossover was assumed to be unidirectional, from the control to the treatment arm. 
Two assumptions on the crossover probabilities were made: in one case, the probability did 
not change between the two prognostic groups and was chosen to be 0.50; in the other 
case, patients “at high risk” were considered more likely to crossover, with a probability of 
0.80, while for patients “at low risk” the probability was set to be 0.20.  
These probabilities were then used to generate a binary variable representing the presence 
or the absence of crossover for each patient. If present, crossover was assumed to have 
occurred after 1 year from randomisation. 
 
The summary of all the simulation scenarios is given in Table 3.1. 
For each scenario, 1000 different datasets were generated as described in this paragraph, 
and the various methods applied to each dataset.  
Simulations were made using the R statistical software, and the STATA packages stcomply 
[12] and strbee [13].   
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Table 3.1 – Summary of the simulation scenarios 
# 
Scenario 
 
Treatment effect  
(ln(HR)) 
 % good prognosis 
 
Crossover probabilities* 
  = % at low risk 
 
% good 
prognosis 
% poor 
prognosis 
1  - 0.598  30 
 
50 50 
2  - 0.598  30 
 
20 80 
3  - 0.598  70 
 
50 50 
4  - 0.598  70 
 
20 80 
5  -0.223  30  50 50 
6  -0.223  30  20 80 
7  -0.223  70  50 50 
8  -0.223  70  20 80 
9  0  30  50 50 
10  0  30  20 80 
11  0  70  50 50 
12  0  70  20 80 
* Computed on patients who reach 1 year after randomization 
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3.2. Performance measures 
Criteria for evaluating the performance of the obtained results from the different scenarios 
and statistical approaches are summarised in this paragraph. Performance measures as 
described in Burton et al [14] were used in order to compare the simulated results with the 
true values used to generate the data. They include an assessment of bias, accuracy and 
coverage. 
 
The bias of each method was calculated as 
δ = ?̅̂? − 𝛽, 
where 𝛽 is the true initial treatment effect for the scenario under study, and ?̅̂? = ∑ 𝛽?̂?
𝐵
𝑖=1 /𝐵, 
𝛽𝑖 is the estimate of interest within each of the i = 1,…, B simulations. 
 
The mean square error (MSE) provides a useful measure of the overall accuracy, as it 
incorporates both measures of bias and variability. 
 
Coverage is defined as the proportion of times the 100(1 - α)% confidence interval (i.e. 
95% confidence interval) for a particular method contains the true treatment effect, 𝛽. The 
coverage should be approximately equal to the nominal coverage rate, e.g. 95 per cent of 
samples for 95% confidence intervals, to appropriately control the type I error rate for 
testing a null hypothesis of no effect. Over-coverage, where the coverage rates are above 
95%, suggests that the results are too conservative: more simulations will not find a 
significant result when there is a true effect, leading to a loss of statistical power with too 
many type II errors. Conversely, under-coverage, where the coverage rates are lower than 
95%, indicates over-confidence in the estimates: more simulations will incorrectly detect a 
significant result, which leads to higher than expected type I errors. 
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In Table 3.2. the considered performance measures and formulas are given. 
 
Table 3.2 – Performance measures 
Evaluation criteria  Formula 
BIAS  
 
Bias  δ = ?̅̂? − 𝛽 
Percentage bias  (
?̅̂? − 𝛽
𝛽
) ∗ 100 
Standardised bias  (
?̅̂? − 𝛽
𝑆𝐸(?̂?)
) ∗ 100 
ACCURACY   
Mean square error  (?̅̂? − 𝛽)
2
+  (𝑆𝐸(?̂?))
2
 
COVERAGE  
Proportion of times the 100(1 - α)% confidence interval 
𝛽?̂? ± 𝑍1−α
2
𝑆𝐸(𝛽?̂?) include 𝛽, for i = 1,…, B 
 
 
𝑆𝐸(?̂?)= √
1
(𝐵−1)
∑ (𝛽?̂? − ?̅̂?)
2
𝐵
𝑖=1  is the empirical standard error, and it represents an 
assessment of the uncertainty in the estimate of interest between simulations. 
An alternative measure of uncertainty is the average of the estimated within simulation SE 
for the estimate of interest ∑ SE(βî)
B
i=1 /B. 
The empirical SE should be close to the average of the estimated within simulation SE if 
the estimates are unbiased, so it may be appropriate to consider both estimates of 
uncertainty. 
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Chapter 4 
Results of the simulation study 
 
The results of the simulations for the different scenarios are reported in Tables 4.1-4.12. 
 
Scenarios from 1 to 4, reproducing a trial in which the experimental treatment is highly 
effective (β = -0.598), are reported in Tables 4.1-4.4. 
In the first scenario (Table 4.1), the patients are mostly at high risk (only 30% are at good 
prognosis) and the crossover does not depend on prognosis, but the probability to switch is 
the same, i.e. 50%, for patients at low and high risk. It is clear from the simulation that the 
ITT analysis gives the most biased results. The other methods, both naïve and non-naïve, 
perform better; the method by Loeys and Goetghebeur gives a low biased estimate, but 
with a wider confidence interval, while the RPSFTM performs particularly well, with a 
very low biased and accurate estimate. When adjusted by prognosis, the IPCW method 
gives an unbiased and very accurate estimate. 
The second scenario (Table 4.2) reproduces a trial similar to the one in the first scenario, 
but considers different probabilities to cross over for the two prognosis groups, with a 
higher probability for patients with a poor prognosis (20% among patients with a good 
prognosis, 80% for patients with a poor prognosis). ITT analysis still gives biased results, 
but the other naïve methods also do not perform well. The Loeys and Goetghebeur and the 
RPSFTM methods give low biased results. Also in this case, when adjusted by prognosis, 
the IPCW method gives an estimate which is the most similar to the true value of the 
effect. 
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In scenarios 3 and 4 (Tables 4.3 and 4.4), trials similar to the ones of the first and second 
scenario, respectively, are reproduced, with the difference that the patients are mostly at 
low risk (70% are at good prognosis). Results are similar to the ones observed for the first 
two scenarios: when the crossover probability does not depend on prognosis, all the 
considered methods perform well, except the ITT which underestimates the true effect; 
when the crossover probability depends on prognosis, all the naïve methods and the 
unadjusted IPCW method give biased results, while the Loeys and Goetghebeur and the 
RPSFTM approaches perform well. Again, when adjusted by prognosis, the IPCW method 
provides an unbiased and accurate estimate. 
 
Scenarios from 5 to 8, reproducing a trial in which the experimental treatment is less 
effective than in previous scenarios (β = -0.223), are reported in Tables 4.5-4.8. 
In scenario 5 (Table 4.5), patients are mostly at high risk (30% are at good prognosis) and 
the crossover probability is the same, i.e. 50%, for patients at low and high risk. The ITT is 
still the method that gives the most biased results, although the bias is lower if compared to 
the one observed in the first scenario (that is identical to scenario 5, except for the value of 
the true treatment effect). The other methods, both naïve and non-naïve perform well, with 
the Loeys and Goetghebeur and the RPSFTM approaches giving wider confidence 
intervals if compared to the other methods, with the RPSFTM tending to slightly 
overestimate the treatment effect. 
In scenario 6 (Table 4.6), a trial similar to the one in scenario 5 is reproduced, but the 
probability to cross over is higher for patients with a poor prognosis (20% among patients 
with a good prognosis, 80% for patients with a poor prognosis). All the naïve methods do 
not perform well, but in particular the model in which the treatment is considered as a 
time-dependent covariate gives results with the higher bias. Also the unadjusted IPCW 
analysis does not perform well. The method by Loeys and Goetghebeur and the RPSFTM 
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give low biased results, again with the RPSFTM tending to slightly overestimate the 
treatment effect. 
Similar results to the ones observed in scenarios 5 and 6 are obtained in scenarios 7 and 8, 
respectively (Table 4.7 and 4.8), which reproduce trials similar to the previous two 
scenarios, with the difference that the patients are mostly at low risk (70% are at good 
prognosis). 
Basically across all these scenarios, it is easy to see that, when adjusted by prognosis, the 
IPCW method has always a good performance. 
 
Scenarios from 9 to 12, reproducing a trial in which the experimental treatment has no 
effect (β = 0), are reported in Tables 4.9-4.12. It was not possible to determine the 
percentage bias for these scenarios, because of the nullity of the parameter posed at the 
denominator of the performance measure. 
Scenario 9 (Table 4.9) considers a trial in which patients are mostly at high risk (30% are 
at good prognosis) and the crossover probability is the same, i.e. 50%, for patients at low 
and high risk. In this case, the ITT is the method which performs better. The other 
approaches perform well, too, with the RPSFTM and the unadjusted IPCW analysis 
presenting a slightly higher bias. 
The following scenario (Table 4.10) reproduces a trial similar to the one in scenario 9, but 
with different probabilities to cross over for the two prognosis groups (20% among patients 
with a good prognosis, 80% for patients with a poor prognosis). ITT analysis still gives 
low biased results, along with the Loeys and Goetghebeur method and the adjusted IPCW 
analysis. The censored analysis and the analysis which considers the treatment as a time 
dependent variable lead to biased results, along with the unadjusted IPCW analysis. 
In scenarios 11 and 12 (Tables 4.11 and 4.12), trials similar to the ones in scenarios 9 and 
10, respectively, are reproduced, but with patients mostly at low risk (70% are at good 
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prognosis). Results are similar to the ones observed for the previous two scenarios. When 
the crossover probability does not depend on prognosis, all the methods perform well, the 
unadjusted IPCW being the one which leads to a higher bias. When the crossover 
probability depends on prognosis, the ITT still gives low biased results, along with the 
Loeys and Goetghebeur; while the other naïve methods and the unadjusted IPCW lead to 
high biased estimates.  
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SCO = selective crossover; ITT = Intention to treat; TD-COV = time dependent covariate; RPSFTM = Rank Preserving Structural Failure Time Model; IPCW = 
inverse probability of censoring weighting 
CI = confidence interval; STD = standardised; MSE = mean square error; SE = standard error 
 
Table 4.1. Results from scenario 1 (% at good prognosis = 30; crossover probabilities among patients at: good prognosis = 50, poor prognosis = 50) 
True effect  95% CI        
β = -0.598 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.567 -0.571 -0.563 0.031 -5.190 48.890 0.005 0.063 0.065 0.936 
ITT -0.419 -0.423 -0.415 0.179 -29.955 273.810 0.036 0.065 0.066 0.233 
CENSORED -0.571 -0.576 -0.567 0.027 -4.441 38.028 0.006 0.070 0.071 0.939 
TD - COV -0.575 -0.579 -0.571 0.023 -3.855 34.554 0.005 0.067 0.068 0.941 
Loeys & Goetghebeur -0.560 -0.808 -0.327 0.038 -6.282 32.979 0.014 0.114 0.123 0.948 
RPSFTM -0.591 -0.785 -0.384 0.007 -1.120 8.348 0.006 0.080 0.102 0.949 
IPCW (unadjusted) -0.563 -0.568 -0.559 0.035 -5.772 49.578 0.006 0.070 0.071 0.922 
IPCW (adjusted by 
prognosis) 
-0.599 -0.604 -0.595 -0.001 0.259 -2.143 0.005 0.072 0.071 0.949 
 
Table 4.2. Results from scenario 2 (% at good prognosis = 30; crossover probabilities among patients at: good prognosis = 20, poor prognosis = 80) 
True effect  95% CI        
β = -0.598 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.567 -0.571 -0.563 0.031 -5.190 48.890 0.005 0.063 0.065 0.936 
ITT -0.347 -0.351 -0.343 0.251 -42.020 377.501 0.068 0.067 0.067 0.034 
CENSORED -0.364 -0.368 -0.359 0.234 -39.149 324.441 0.060 0.072 0.076 0.124 
TD - COV -0.306 -0.310 -0.302 0.292 -48.827 426.496 0.090 0.068 0.072 0.011 
Loeys & Goetghebeur -0.582 -0.784 -0.384 0.016 -2.750 17.356 0.009 0.095 0.102 0.960 
RPSFTM -0.593 -0.772 -0.416 0.005 -0.786 7.028 0.004 0.067 0.091 0.951 
IPCW (unadjusted) -0.409 -0.414 -0.405 0.189 -31.557 260.893 0.041 0.072 0.075 0.285 
IPCW (adjusted by 
prognosis) 
-0.600 -0.605 -0.595 -0.002 0.346 -2.531 0.007 0.082 0.079 0.955 
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Table 4.3. Results from scenario 3 (% at good prognosis = 70; crossover probabilities among patients at: good prognosis = 50, poor prognosis = 50) 
True effect  95% CI        
β = -0.598 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.552 -0.557 -0.547 0.045 -7.605 57.079 0.008 0.080 0.083 0.923 
ITT -0.406 -0.411 -0.401 0.192 -32.047 230.299 0.044 0.083 0.085 0.383 
CENSORED -0.556 -0.562 -0.551 0.042 -6.949 47.466 0.009 0.088 0.091 0.934 
TD - COV -0.560 -0.565 -0.555 0.038 -6.288 45.588 0.008 0.082 0.087 0.934 
Loeys & Goetghebeur -0.548 -0.827 -0.289 0.050 -8.318 39.788 0.018 0.125 0.137 0.948 
RPSFTM -0.592 -0.831 -0.352 0.006 -0.953 4.586 0.015 0.124 0.122 0.966 
IPCW (unadjusted) -0.546 -0.551 -0.540 0.052 -8.748 59.869 0.010 0.087 0.091 0.916 
IPCW (adjusted by 
prognosis) 
-0.600 -0.605 -0.594 -0.002 0.279 -1.778 0.009 0.094 0.091 0.946 
 
Table 4.4. Results from scenario 4 (% at good prognosis = 70; crossover probabilities among patients at: good prognosis = 20, poor prognosis = 80) 
True effect  95% CI        
β = -0.598 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.552 -0.557 -0.547 0.045 -7.605 57.079 0.008 0.080 0.083 0.923 
ITT -0.396 -0.401 -0.391 0.202 -33.784 241.910 0.048 0.083 0.085 0.355 
CENSORED -0.348 -0.354 -0.343 0.250 -41.736 278.541 0.070 0.090 0.091 0.205 
TD - COV -0.251 -0.256 -0.245 0.347 -58.093 411.233 0.128 0.084 0.086 0.017 
Loeys & Goetghebeur -0.559 -0.828 -0.305 0.039 -6.443 31.287 0.017 0.123 0.133 0.955 
RPSFTM -0.593 -0.826 -0.358 0.005 -0.886 4.170 0.016 0.127 0.120 0.965 
IPCW (unadjusted) -0.379 -0.385 -0.373 0.219 -36.605 246.412 0.056 0.089 0.090 0.315 
IPCW (adjusted by 
prognosis) 
-0.601 -0.607 -0.595 -0.003 0.553 -3.344 0.010 0.099 0.095 0.933 
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Table 4.5. Results from scenario 5 (% at good prognosis = 30; crossover probabilities among patients at: good prognosis = 50, poor prognosis = 50) 
True effect  95% CI        
β = -0.223 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.209 -0.212 -0.205 0.015 -6.554 25.493 0.004 0.057 0.059 0.954 
ITT -0.149 -0.153 -0.146 0.074 -33.060 126.057 0.009 0.059 0.060 0.776 
CENSORED -0.210 -0.214 -0.206 0.013 -5.920 20.817 0.004 0.063 0.066 0.960 
TD - COV -0.211 -0.215 -0.207 0.012 -5.493 20.041 0.004 0.061 0.064 0.962 
Loeys & Goetghebeur -0.206 -0.419 -0.001 0.017 -7.782 17.095 0.011 0.102 0.107 0.957 
RPSFTM -0.238 -0.425 -0.020 -0.015 6.547 -13.900 0.011 0.105 0.103 0.952 
IPCW (unadjusted) -0.202 -0.206 -0.198 0.021 -9.296 32.810 0.004 0.063 0.066 0.944 
IPCW (adjusted by 
prognosis) 
-0.224 -0.228 -0.220 -0.001 0.247 -0.819 0.005 0.067 0.066 0.947 
 
Table 4.6. Results from scenario 6 (% at good prognosis = 30; crossover probabilities among patients at: good prognosis = 20, poor prognosis = 80) 
True effect  95% CI        
β = -0.223 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.209 -0.212 -0.205 0.015 -6.554 25.493 0.004 0.057 0.059 0.954 
ITT -0.122 -0.126 -0.119 0.100 -45.104 171.548 0.014 0.059 0.060 0.611 
CENSORED -0.016 -0.020 -0.012 0.208 -93.007 313.614 0.047 0.066 0.071 0.150 
TD - COV 0.042 0.038 0.046 0.265 -118.908 420.413 0.074 0.063 0.069 0.019 
Loeys & Goetghebeur -0.216 -0.394 -0.041 0.007 -3.007 7.826 0.007 0.086 0.090 0.955 
RPSFTM -0.243 -0.406 -0.059 -0.020 9.081 -21.847 0.009 0.093 0.088 0.954 
IPCW (unadjusted) -0.059 -0.063 -0.055 0.164 -73.589 248.918 0.031 0.066 0.070 0.344 
IPCW (adjusted by 
prognosis) 
-0.222 -0.227 -0.217 0.001 -0.547 1.639 0.006 0.075 0.074 0.954 
 
  
36 
Table 4.7. Results from scenario 7 (% at good prognosis = 70; crossover probabilities among patients at: good prognosis = 50, poor prognosis = 50) 
True effect  95% CI        
β = -0.223 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.203 -0.208 -0.199 0.020 -8.946 28.628 0.005 0.070 0.076 0.961 
ITT -0.145 -0.149 -0.141 0.078 -35.043 110.143 0.011 0.070 0.077 0.835 
CENSORED -0.207 -0.212 -0.203 0.016 -7.071 20.655 0.006 0.076 0.084 0.963 
TD - COV -0.209 -0.214 -0.205 0.014 -6.221 18.840 0.006 0.074 0.081 0.964 
Loeys & Goetghebeur -0.204 -0.438 0.018 0.019 -8.700 18.420 0.011 0.105 0.117 0.968 
RPSFTM -0.225 -0.456 0.023 -0.001 0.673 -1.227 0.015 0.122 0.122 0.959 
IPCW (unadjusted) -0.197 -0.202 -0.192 0.026 -11.754 34.458 0.006 0.076 0.084 0.957 
IPCW (adjusted by 
prognosis) 
-0.227 -0.232 -0.221 -0.003 1.533 -4.122 0.007 0.083 0.084 0.952 
 
Table 4.8. Results from scenario 8 (% at good prognosis = 70; crossover probabilities among patients at: good prognosis = 20, poor prognosis = 80) 
True effect  95% CI        
β = -0.223 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.203 -0.208 -0.199 0.020 -8.946 28.628 0.005 0.070 0.076 0.961 
ITT -0.141 -0.145 -0.137 0.082 -36.809 114.963 0.012 0.071 0.077 0.834 
CENSORED -0.003 -0.008 0.001 0.220 -98.506 282.992 0.054 0.078 0.084 0.235 
TD - COV 0.093 0.089 0.098 0.317 -141.879 428.269 0.106 0.074 0.080 0.009 
Loeys & Goetghebeur -0.209 -0.439 0.013 0.014 -6.333 13.546 0.011 0.104 0.115 0.968 
RPSFTM -0.216 -0.449 0.019 0.007 -3.094 6.122 0.013 0.113 0.119 0.948 
IPCW (unadjusted) -0.033 -0.038 -0.029 0.190 -85.020 246.121 0.042 0.077 0084 0.377 
IPCW (adjusted by 
prognosis) 
-0.225 -0.231 -0.220 -0.002 1.048 -2.705 0.007 0.086 0.087 0.946 
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Table 4.9. Results from scenario 9 (% at good prognosis = 30; crossover probabilities among patients at: good prognosis = 50, poor prognosis = 50) 
True effect  95% CI        
β = 0 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.002 -0.005 0.002 -0.002 - -2.927 0.003 0.055 0.057 0.959 
ITT 0.000 -0.004 0.003 0.000 - -0.638 0.003 0.053 0.057 0.966 
CENSORED -0.001 -0.004 0.003 -0.001 - -0.902 0.004 0.060 0.063 0.966 
TD - COV -0.001 -0.004 0.003 -0.001 - -1.050 0.003 0.058 0.062 0.961 
Loeys & Goetghebeur 0.001 -0.196 0.193 0.001 - 0.706 0.009 0.097 0.099 0.962 
RPSFTM -0.028 -0.184 0.246 0.028 - 27.297 0.011 0.101 0.110 0.968 
IPCW (unadjusted) 0.007 0.003 0.011 0.007 - 11.636 0.004 0.059 0.063 0.963 
IPCW (adjusted by 
prognosis) 
-0.001 -0.005 0.003 -0.001 - -1.266 0.004 0.063 0.063 0.958 
 
Table 4.10. Results from scenario 10 (% at good prognosis = 30; crossover probabilities among patients at: good prognosis = 20, poor prognosis = 80) 
True effect  95% CI        
β = 0 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO -0.002 -0.005 0.002 -0.002 - -2.927 0.003 0.055 0.057 0.959 
ITT 0.001 -0.002 0.004 0.001 - 1.663 0.003 0.055 0.057 0.965 
CENSORED 0.189 0.185 0.193 0.189 - 294.866 0.040 0.064 0.068 0.188 
TD - COV 0.247 0.244 0.251 0.247 - 405.783 0.065 0.061 0.066 0.020 
Loeys & Goetghebeur -0.001 -0.167 0.165 -0.001 - -0.900 0.006 0.079 0.085 0.968 
RPSFTM 0.016 -0.165 0.192 0.016 - 22.123 0.005 0.072 0.091 0.962 
IPCW (unadjusted) 0.147 0.143 0.151 0.147 - 229.179 0.026 0.064 0.068 0.419 
IPCW (adjusted by 
prognosis) 
-0.001 -0.005 0.004 -0.001 - -0.897 0.005 0.072 0.071 0.945 
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Table 4.11. Results from scenario 11 (% at good prognosis = 70; crossover probabilities among patients at: good prognosis = 50, poor prognosis = 50) 
True effect  95% CI        
β = 0 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO 0.001 -0.003 0.005 0.001 - 1.274 0.005 0.068 0.072 0.963 
ITT 0.000 -0.004 0.004 0.000 - -0.203 0.005 0.069 0.072 0.955 
CENSORED 0.000 -0.004 0.005 0.000 - 0.525 0.006 0.078 0.081 0.959 
TD - COV 0.001 -0.004 0.005 0.001 - 0.908 0.006 0.075 0.078 0.963 
Loeys & Goetghebeur 0.003 -0.211 0.206 0.003 - 2.667 0.010 0.099 0.106 0.959 
RPSFTM 0.003 -0.243 0.243 0.003 - 1.975 0.019 0.139 0.124 0.958 
IPCW (unadjusted) 0.011 0.006 0.015 0.011 - 13.594 0.006 0.077 0.081 0.952 
IPCW (adjusted by 
prognosis) 
0.001 -0.004 0.006 0.001 - 1.230 0.007 0.084 0.081 0.942 
 
Table 4.12. Results from scenario 12 (% at good prognosis = 70; crossover probabilities among patients at: good prognosis = 20, poor prognosis = 80) 
True effect  95% CI        
β = 0 β̅̂ Lower Upper Bias Percentage BIAS STD Bias MSE Empirical SE Average SE Coverage 
In absence of SCO 0.001 -0.003 0.005 0.001 - 1.274 0.005 0.068 0.072 0.963 
ITT 0.001 -0.003 0.005 0.001 - 1.731 0.005 0.069 0.072 0.956 
CENSORED 0.202 0.197 0.206 0.202 - 260.421 0.047 0.077 0.081 0.289 
TD - COV 0.299 0.294 0.303 0.299 - 403.700 0.095 0.074 0.078 0.021 
Loeys & Goetghebeur -0.001 -0.214 0.205 -0.001 - -1.133 0.010 0.102 0.107 0.956 
RPSFTM -0.010 -0.240 0.232 -0.010 - -7.257 0.018 0.133 0.120 0.850 
IPCW (unadjusted) 0.172 0.167 0.176 0.172 - 224.612 0.035 0.076 0.081 0.430 
IPCW (adjusted by 
prognosis) 
0.003 -0.003 0.008 0.003 - 3.129 0.007 0.086 0.084 0.952 
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Chapter 5 
Discussion, conclusions and hints for future 
research 
 
1.1. Discussion 
When a RCT is designed to compare the difference in (disease-free) survival time between 
two treatment groups, letting patients switch treatment may critically complicate the 
statistical analysis and interpretation of results. 
As emerged from the literature review in Chapter 1, this phenomenon is quite common 
among trials assessing the efficacy of biological drugs and hormonal therapies for breast 
cancer, as over one out of five let patients in the control arm cross over to receive the 
intervention under study, at a certain point after randomisation. The ITT analysis was 
always reported; by the way, as already explained, this approach may not be appropriate, 
tending to underestimate the actual treatment effect, in the hypothesis that the treatment is 
more effective than the regimen administered in the control. The review highlighted also 
the fact that, if present, other types of analyses conducted were usually based on naïve 
methods, i.e. the censored analysis. Only in a very few cases, results from a more complex 
method, i.e. IPCW, were reported. 
Chapter 2 presented these methods along with others that can be helpful to deal with SCO: 
naïve methods, i.e. treatment considered as a time dependent variable, and more complex 
methods, i.e. Loeys and Goetghebeur estimator, and the RPSFTM by Robins and Tsiatis. 
The results of the simulation study, presented in Chapter 4, confirmed that the ITT 
analysis, although the most used approach, tends to underestimate the true treatment effect 
across all the considered scenarios, but it performs quite well in the extreme case that the 
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treatment under study does not have an impact on survival if compared to control regimen. 
Other naïve methods – such as censoring switching patients at the time of crossover, or 
incorporating treatment received as a time-dependent covariate – performed well, with low 
levels of bias, when the probability of crossing over was assumed to be the same for 
patients with different prognosis; if patients with a poor prognosis were assumed to have a 
higher probability to cross over, these methods led to biased results, underestimating the 
true treatment effect. 
As far as more complex methods is concerned, the estimator proposed by Loeys & 
Goetghebeur did perform quite well across all scenarios, even if it tended to present wider 
confidence intervals if compared to the other methods. By the way, this approach is based 
on the “all-or-nothing” assumption, which is unlikely to hold in a context as the one 
considered. 
The RPSFTM approach led to low biased estimates across the various scenarios, but 
tending to have wider confidence intervals, as for the Loeys & Goetghebeur method. The 
common treatment effect assumption, considered by this method, which states that the 
effect does not change in relation to the time in which a patient starts receiving the 
treatment, is strong and can be difficult to justify in a real context. 
The unadjusted IPCW analysis could estimate the true treatment effect with low bias when 
the probability of crossover was the same for the two prognosis classes, otherwise it did 
not perform well, in particular with if the treatment has a moderate or no effect. Across all 
the scenarios, when adjusted by prognosis, the IPCW method had always a good 
performance; this highlights the importance of knowing the characteristics that may favour 
the crossover, in order to obtain an unbiased and accurate estimate of the treatment effect. 
By the way it is not easy, as emerged from the literature review, to understand from the 
papers reporting trials’ results which are the characteristics that may influence the choice 
of a patient to switch arm. 
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1.2. Conclusions and hints for future research 
The present work aimed to highlight the need for attention being paid on the phenomenon 
of SCO in RCTs. This thesis, in fact, underlines the concerns related to it, but further 
research is still necessary. 
A more comprehensive medical literature research would be helpful to better estimate the 
prevalence of SCO in trials evaluating interventions for breast cancer, but it would be 
important to explore other medical fields, too. A systematic review of all methodological 
papers dealing with the methods to adjust for SCO and published in the literature may lead 
to have other methods to consider, not analysed in this thesis. 
The simulations performed for this work can be adapted to create scenarios in which there 
are more than two prognosis categories, with different probabilities to cross over. It could 
be appropriate to overcome the limitation for which, when present, the crossover occurs 
after 1 year, letting this time change among patients, and to see the impact this 
modification can have on the performances of the different methods. 
Although simulations are necessary, it would be interesting to apply the described methods 
to a real dataset from a trial in which SCO has occurred. 
 
Clinical decisions are based on RCTs’ results, so appropriate analyses and interpretations 
are crucial. Systematic reviews and meta-analyses, from which clinical guidelines and 
recommendations derive, may include trials in which SCO has occurred [3,4]: further 
research should evaluate the impact of SCO on the summary results of the meta-analysis. 
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